Drug discovery, a long and high-cost process, is confronted with low productivity and great challenges when using animals to discover new drugs. To achieve a high efficacy in drug screening and minimize animal assays, Creative Bioarray has been dedicated to developing cell-based high-throughput screening (HTS) platforms which provide more biological relevance than biochemical assays, and thus help you to reduce the number of animal tests and speed up the drug development process.
HTS can be categorized into two classes, namely target-based biochemical assays and cell-based assays. Because biochemical assays cannot precisely predict real responses to compounds in a cellular context, drug investigators are prone to perform screening with cell-based assays in recent years.
At Creative Bioarray, cell-based high-throughput screening (HTS) platforms are used for fast screening of drug leads in a large scale. At the onset of any HTS project, our frozen stock of in vitro cell models will be generated in a 96-well format to maintain the desired bioactivity and also render reproducibility. With our extensive expertise and experiences in cell culture, Creative Bioarray can develop cell models from a wide range of cells tailored to your specifications, including commercial cell lines, primary cells and in vitro disease models, which provide better prediction for future preclinical tests by maximizing the physiological relevance.
Depending on the variables to be measured, cell responses to candidate compounds can be reflected by biochemical readouts with fluorescence, luminescence, colorimetric or radioactivity in an automated way. Creative Bioarray exploit high/live content imaging to observe and record morphologic changes of the cell cultures.
Creative Bioarray is staffed by experts in design and optimization of cell based HTS assays. We aim at making the best efforts to provide relevant and predictive readouts, and thus save cost and accelerate the process in your future validation of drugs.